Clonal hematopoiesis is associated with cardiovascular events in patients with stable coronary artery disease

• DOI: 10.1016/j.isci.2024.109472
• Publication Date: 2024-03-11T17:25:57Z
• Authors: Mihaela I. Dregoesc; Helin Tercan; Adrian B. Țigu; Siroon Bekkering; Leo AB. Joosten; Mihai G. Netea; Rosanne C. van De...; Alexander Hoischen; Niels P. Riksen; Adrian C. Iancu
• Keywords: Mace; Hematology

Clonal hematopoiesis (CH) is a risk factor for atherosclerotic cardiovascular disease, but the impact of smaller clones and effect on inflammatory parameters largely unknown. Using ultrasensitive single-molecule molecular inversion probe sequencing, we evaluated association between CH first major adverse event (MACE) in patients with angiographically documented stable coronary artery disease (CAD) no history acute ischemic events. was associated an increased rate MACE at four years follow-up. The size clone predicted optimal cut-off value 1.07% variant allele frequency (VAF). Mutation carriers had change monocytes subsets or cytokine production capacity higher levels circulating tissue factor, matrilysin, proteinase-activated receptor-1. Our study identified driver mutations VAF as small residual potential biomarkers therapeutic targets CAD.